FTO and acute myeloid leukemia: Targeting FTO could reduce immune checkpoint gene expression, especially LILRB4, consequently enhancing AML cell sensitivity to T cell cytotoxicity and overcoming the hypomethylating agent decitabine-induced immune evasion.